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Abstract
Introduction: Diclofenac, a nonsteroidal antiinflammatory drug, is commonly used as antipyretic therapy in
intensive care. The purpose of this study was to investigate the effects of parenteral diclofenac infusion on brain
homeostasis, including brain-tissue oxygen tension (PbtO2) and brain metabolism after aneurysmal subarachnoid
hemorrhage (aSAH).
Methods: We conducted a prospective, observational study with retrospective analysis of 21 consecutive aSAH
patients with multimodal neuromonitoring. Cerebral perfusion pressure (CPP), mean arterial pressure (MAP),
intracranial pressure (ICP), body temperature, and PbtO2 were analyzed after parenteral diclofenac infusion
administered over a 34-minute period (20 to 45 IQR). Data are given as mean ± standard error of mean and
median with interquartile range (IQR), as appropriate. Time-series data were analyzed by using a general linear
model extended by generalized estimation equations (GEEs).
Results: One-hundred twenty-three interventions were analyzed. Body temperature decreased from 38.3°C ± 0.05°C
by 0.8°C ± 0.06°C (P < 0.001). A 10% decrease in MAP and CPP (P < 0.001) necessitated an increase of vasopressors
in 26% (n = 32), colloids in 33% (n = 41), and crystalloids in 5% (n = 7) of interventions. PbtO2 decreased by 13%
from a baseline value of 28.1 ± 2.2 mm Hg, resulting in brain-tissue hypoxia (PbtO2 <20 mm Hg) in 38% (n = 8) of
patients and 35% (n = 43) of interventions. PbtO2 <30 mm Hg before intervention was associated with brain-tissue
hypoxia after parenteral diclofenac infusion (likelihood ratio, 40; AUC, 93%; 95% confidence interval (CI), 87% to
99%; P < 0.001). Cerebral metabolism showed no significant changes after parenteral diclofenac infusion.
Conclusions: Parenteral diclofenac infusion after aSAH effectively reduces body temperature, but may lead to CPP
decrease and brain-tissue hypoxia, which were both associated with poor outcome after aSAH.
Introduction
Fever is common in patients with aneurysmal subarach-
noid hemorrhage (aSAH) and independently associated
with poor outcome [1-4]. Brain-temperature elevations
correlate with an increase of cerebral metabolic rate of
oxygen (CMRO2) [5], intensified brain metabolism [6],
aggravation of cerebral edema, and increased intracranial
pressure (ICP) [7]. The hypothalamic set-point tempera-
ture can be lowered with nonsteroidal antiinflammatory
drugs (NSAIDs) through inhibition of prostaglandine-E2
(PGE2) synthesis [8]. The NSAID diclofenac is commonly
used in intensive care units for fever treatment [9-11]. Side
effects of parenteral diclofenac, such as decrease of mean
arterial blood pressure (MAP) [11] and cerebral perfusion
pressure (CPP) [10,12], have been previously described.
Hemodynamic stability for maintaining adequate cerebral
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perfusion during vasospasm is of utmost importance after
aSAH [13]. The prognostic significance of low CPP and
episodes of brain-tissue hypoxia (PbtO2 <20 mm Hg) after
aSAH and traumatic brain injury (TBI) has been exten-
sively studied [14-17]. The purpose of this trial was to
describe the effects of parenteral diclofenac infusion on
CPP, brain-tissue oxygen tension (PbtO2), and brain meta-
bolism in the early period of aSAH.
Materials and methods
Patients
Prospectively collected data of 29 consecutive a SAH
patients with brain multimodal neuromonitoring between
September 2010 and March 2012 were retrospectively ana-
lyzed. Twenty-one patients receiving parenteral diclofenac
infusion during the neuromonitoring time were included
(see Additional file 1). Criteria for invasive neuromonitor-
ing were approved by the institutional review board of
Innsbruck Medical University (UN3898 285/4.8) as
follows: (a) GCS ≤8, (b) poor likelihood for regaining
consciousness within the following 48 hours, (c) high like-
lihood for surviving at least 48 hours, and (d) age older
than 18 years. Written informed consent was obtained
according to federal regulations.
General management
In general, patient care conformed to guidelines of the
American Heart Association [18]. Patients were clinically
graded with the Hunt and Hess scale and radiologically
assessed with the modified Fisher scale [19] of the first
available cerebral computed tomography (CT) scan.
Prophylactic, parenteral continuous nimodipine (1 to 2
mg/hour) was routinely given in all patients. A mean flow
velocity >200 cm/second of the basal cerebral arteries
assessed with transcranial Doppler sonography (TCD,
DWL Doppler-Box system; Compumedics, Singen, Ger-
many) was considered as TCD flow-velocity acceleration.
Catheter angiography was performed in patients with
TCD flow-velocity acceleration. Patients with angiographic
vasospasm were treated with intraarterial nimodipine and
vasopressors. All patients included in this study had con-
tinuous invasive blood pressure monitoring. Fluid therapy
(colloids or crystalloids) were used as first-line, and vaso-
pressors (noradrenaline, phenylephrine, or dobutamine)
were used as second-line therapy for maintaining MAP
and CPP. Whenever a critical CPP <50 mm Hg was
reached, vasopressors were started/increased immediately.
In case of unexpected blood pressure decreases, the par-
enteral nimodipine dose was decreased or stopped.
We did not perform wake-up trials on the patients, fol-
lowing our institutional guidelines. Therefore, delayed
cerebral infarction (DCI) was defined as any new infarct
appearing on cerebral CT scan that was judged by an
independent radiologist to be attributable to vasospasm.
Pneumonia was defined as radiologic infiltrate and
elevated white blood cell count. Start and finish time of
any pharmacologic intervention, including dosage,
were exactly documented in the electronic patient data-
management system (PDMS; Centricity Critical Care 7.0,
General Electric Healthcare Company, IL, USA).
Fever definitions and management
Body temperature was measured with the temperature
sensor of the bladder catheter. Fever was defined as a body
temperature >38.4°C because this was the threshold for
fever treatment. In certain cases, fever therapy was
initiated at lower body temperatures at the discretion of
the intensive care physician. Parenteral diclofenac (75 mg;
maximum dosage, 150 mg/day) or parenteral acetamino-
phen (1,000 mg; maximum dosage, 3,000 mg/day) was
used as first-line antipyretic therapy. The choice of treat-
ment was at the discretion of the treating intensivist.
In case of ineffectiveness or contraindications against the
first-line antipyretic treatment (meperidine; Pethidine; 100
mg; maximum, 400 mg/day) as second-line therapy was
given. If temperature still remained above 38.4°C,
normothermia (36.5°C) was maintained in four patients
with an invasive cooling device (CoolGard 3000 or
ThermoGard XP; Alsius Corporation, Zoll Medical
Corporation, MA, USA) as rescue therapy [20].
Interventions
For fever treatment, 75 mg diclofenac-sodium diluted in
100 ml normal saline (Ratiopharm, parenteral diclofenac
(Diclobene), 75 mg, drug approval number: 1-19719) was
administered intravenously. Starting and ending time
points of intervention were exactly documented in the
PDMS. Interventions with administration of other anti-
pyretics or invasive cooling 4 hours before or after par-
enteral diclofenac were excluded (details on the inclusion
algorithm are shown in Appendix Figure 1).
Monitoring and data acquisition
Monitoring probes were placed into the hemisphere
deemed at greatest risk for secondary injury and either
tunneled or fixed by using a triple-lumen bolt. CT scan of
the brain was used to check the probe location, usually
within 24 hours after implantation. PbtO2 was measured
with a Clark-type probe (Licox, Integra, Germany), intra-
cranial pressure (ICP) with an intraparenchymal probe
(Neurovent, Raumedic, Germany). Brain-tissue hypoxia
was defined as brain-tissue oxygen tension <20 mm Hg,
based on previous studies [14,21] demonstrating increased
odds for poor outcome and metabolic distress below this
threshold value. Cerebral microdialysis (CMD) was per-
formed by using a 100-kDa-cutoff microdialysis catheter
(CMA-71; CMA/MicrodialysisTM, Stockholm, Sweden) at
a perfusion rate of 0.3 μl/min. Samples were collected
hourly and frozen at -80°C. Outcome was evaluated
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prospectively 3 months after aSAH with telephone inter-
view by using the modified Rankin Scale (mRS). Poor neu-
rologic outcome was defined as mRS >4. The study nurse
was blinded to the monitoring data and their analysis.
Complications (pneumonia, vasospasm, DCI) were stated
after adjudication of all relevant clinical information in
weekly meetings by the study team (RH, BP, RB, MF, AS,
and ES).
Data management and statistics
The PDMS was used to acquire digital data for ICP, MAP,
CPP, PbtO2 , and body temperature every 3 minutes from
the monitoring device (Carescape B650; General Electric
Company, IL, USA). Monitoring data were averaged to
10-minute mean values. A 10-minute mean average before
intervention was considered a baseline value for a hemo-
dynamic parameter, and 1 hour before intervention was
considered a baseline value for the CMD dataset.
Time-series data were analyzed with a generalized linear
model by using a normal distribution and identity link
function. The model was extended by generalized estimat-
ing equations (GEEs) by using time after intervention as a
factor and important parameters (CPP, body temperature)
as covariates.
An autoregressive matrix of the first order (AR-1) was
used to handle repeated observations within subjects [22].
Logarithmic transformation was applied to meet assump-
tions of normality. Cut-off levels were calculated by using
receiver operating characteristics (ROCs).
SPSS 19.0 was used for statistical testing. P < 0.05 was
considered statistically significant.
Data are given in median and interquartile range (IQR)
or in mean ± one standard error of the mean (SEM).
Results
Study population and intervention
Baseline characteristics are demonstrated in Table 1. Mean
age was 55 ± 11 years, and the median Hunt and Hess
grade was 4 (3 to 5, IQR). Neuromonitoring was initiated
at day 1 (1 to 2, IQR) and maintained for 12 days (8 to 14,
IQR); 29% (n = 6) of patients had poor outcomes.
One-hundred twenty-three interventions were ana-
lyzed. A median of four interventions (two to eight, IQR)
per patient were administered over a 34-minute period
(20 to 45, IQR). Mean central venous pressure at baseline
was 13 ± 0.2 mm Hg. Ten days (7 to 12 days, IQR) after
aSAH was the median time point of intervention, when
fever was most common (30% of daily monitoring time;
Figure 1A).
Effects of parenteral diclofenac infusion on body
temperature
Body temperature at baseline (38.3 ± 0.05°C) decreased by
0.8 ± 0.06°C to a minimum value of 37.5 ± 0.05°C within
330 minutes (260 to 470, IQR) after the start of an inter-
vention (P < 0.001; Figure 1B). In 9% (n = 11) of interven-
tions, temperature did not decrease after parenteral
diclofenac. We found a significant interaction between
body temperature and MAP (P = 0.02), but no interaction
between body temperature and PbtO2.
Effects of parenteral diclofenac infusion on MAP, CPP,
and ICP
MAP (baseline, 93 ± 1.2 mm Hg) and CPP (baseline, 85 ±
1.4 mm Hg) decreased by 10% after intervention (P <
0.001; Figure 2). Maximum blood pressure decreases were
observed 160 minutes (90 to 320, IQR) after intervention.
Figure 1 Fever burden during monitoring time and body temperature after parenteral diclofenac. (A) Cumulative fever burden in percentage
of total monitoring time, fragmented on days after initial hemorrhage (post-bleed day 0-14). Time in fever (temperature >38.4°C) during monitoring
time reached a maximum on post-bleed day 10. (B) demonstrating mean body temperature (●) after parenteral diclofenac (zero on X-axis is the first
10-minute-average-interval during intervention, n = 123; P < 0.001). The width of the dotted bar indicates median infusion time (34 minutes; 20 to 45
IQR). The maximum effect on core body temperature was reached after 330 minutes (median, 260 to 470, IQR). Values are illustrated in mean ± SEM.
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Colloids were administered in 33% (n = 41) and crystal-
loids in 5% (n = 7) 29 minutes (20 to 86, IQR) after inter-
vention. Vasopressors were increased within 75 minutes
(30 to 155 minutes, IQR) in 26% (n = 32) of interventions.
A decrease of CPP <70 mm Hg and <50 mm Hg was
observed in 71% (n = 87) and 12% (n = 15) of interven-
tions, respectively. ICP (baseline: 8.6 ± 0.4 mm Hg) did
not significantly change after intervention.
Effects of parenteral diclofenac infusion on PbtO2
PbtO2 decreased by 13% from a baseline value of 28.1 ± 2.2
mm Hg to 24.5 ± 2.1 mm Hg (P < 0.001; Figure 2), result-
ing in brain-tissue hypoxia (PbtO2 <20 mm Hg) in 35%
(n = 43) of all interventions and in 38% (n = 8) of patients.
This finding remained significant (P < 0.01) after adjusting
for CPP and body temperature, indicating an intrinsic
effect of diclofenac on PbtO2. An interaction occurred
between PbtO2 and CPP (P = 0.02), which is shown in
Figure 3. Baseline PbtO2 <30 mm Hg (Figure 4) was asso-
ciated with brain-tissue hypoxia after parenteral diclofenac
(likelihood ratio, 45; specificity, 81%; sensitivity, 88%; P <
0.001; OR 85.1; 95% CI, 13 to 550), with an area under the
curve (AUC) of 93% (95% CI, 87% to 99%). Brain-tissue
hypoxia was observed 3 hours (1.5 to 3 hours, IQR) after
intervention and persisted for 25 minutes (18 to 180 min-
utes, IQR). A CPP decrease <70 mm Hg was associated
with brain-tissue hypoxia (P < 0.01).
The percentage of total monitoring time with PbtO2
<20 mm Hg (32 ± 9.4% in patients with good outcome
versus 66% ± 12% in patients with poor outcome: OR =
1.04; 95% CI, 1.001 to 1.08; P < 0.05), but not the abso-
lute time (48 ± 20 hours versus 56 ± 27 hours; P = 0.07)
was independently associated with poor outcome after
adjusting for disease severity.
Effects of parenteral diclofenac infusion on cerebral
metabolism
Cerebral microdialysis (CMD) was available in 48% (n =
10) of patients and 28% (n = 34) of interventions. No
significant change in brain metabolism was noted after
parenteral diclofenac (Figure 5) when compared with base-
line values (CMD-lactate, 4 ± 0.3 mM; CMD-pyruvate,
141 ± 7 μM; CMD-LPR, 28 ± 1.5; CMD-glucose, 2 ±
0.2 mM; and CMD-glutamate, 22 ± 8 μM).
Discussion
Our main findings are that parenteral diclofenac infu-
sion after aSAH is associated with a significant decrease
of CPP and brain-tissue oxygen tension. PbtO2 values
<30 mm Hg before intervention were highly predictive
of consecutive brain-tissue hypoxia (PbtO2 <20 mm Hg).
The percentage of time in brain-tissue hypoxia was
independently associated with poor outcome.
PbtO2 reflects the balance between oxygen supply and
demand and can be used as a surrogate marker for cere-
bral blood flow (CBF) [23,24]. The ability to maintain
adequate CBF relatively independent of changes in CPP
is termed normal cerebral autoregulation. Impaired cere-
bral autoregulation frequently occurs after aSAH and
may result in a direct dependence of PbtO2 on CPP [25].
We did not assess cerebral autoregulation, but found a
decrease in CPP related to the decrease in PbtO2. This
mechanism may well explain the PbtO2 decrease in our
patients; especially, a CPP <70 mm Hg was associated
with brain-tissue hypoxia after intervention. This finding
is in line with a recent study indicating a higher risk for
brain-tissue hypoxia at CPP values <70 mm Hg [14].
PbtO2 is dependent not only on oxygen delivery, but also
on cerebral oxygen consumption [23]. Cerebral metabolic
rate of oxygen (CMRO2) as an indicator of cerebral oxygen
Table 1 Demographic details of study patients
Clinical characteristics
Age (years) 56 (47-63)
Gender (female) 13 (62)










IVH sum score 3 (0-6)

















Length of hospital stay
(days)
40 (29-48)




Apache II score (acute physiology and chronic health score); DCI, delayed
cerebral infarction; EVD, external ventricular drainage; H&H, Hunt and Hess grade;
IVH, intraventricular hemorrhage; mFisher scale, modified Fisher scale; mRS,
modified Rankin scale. Data are presented in median (IQR) and count (%).
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consumption is temperature dependent [5]. Experimental
studies showed a reduction of CMRO2 after parenteral
NSAID injection [5]. Therefore, one might expect an
increase of PbtO2 due to reduced CMRO2 after tempera-
ture reduction.
Interestingly, PbtO2 remained decreased even after
CPP had recovered to baseline values. One explanation
for this observation could be the inhibitory effect of
diclofenac on the cyclooxygenase (COX) [26]. PGE2-
syntheses is COX dependent and plays an important
role in maintaining CBF and cerebral autoregulation
[27]. Inhibition of PGE2 synthesis by diclofenac may
reduce CBF and therefore PbtO2. Another explanation
for this prolonged PbtO2 decrease may be neurovascular
coupling, a mechanism of the brain adapting the CBF to
the cerebral ener-gy demand [27]. A decrease in body
temperature might reduce cerebral energy demand and
therefore CBF [5,28]. This hypothesis is furthermore
supported by the lack of metabolic changes despite a
decrease in PbtO2.
We found a significant interaction between mean
arterial blood pressure and body temperature after
diclofenac intervention. This is in line with previously
described hemodynamic changes related to physiological
mechanisms of temperature regulation, including vasodi-
latation, sweating, and inhibition of muscle activity [29].
Hemodynamic changes after parenteral diclofenac
necessitated increased use of vasopressors and parenteral
fluid therapy. Adrenergic stress can promote the develop-
ment of myocardial stunning [30], which may increase
the risk of cerebral infarction from vasospasm, hypoten-
sion, and pulmonary edema [31]. Diclofenac infusion
time was not standardized, which could have influenced
hemodynamic side effects in this study. A randomized
controlled trial by Cormio et al. [12] investigated contin-
uous low-dose diclofenac infusion (0.004 to 0.08 mg/kg
BW/h) for fever management after TBI and aSAH. The
authors showed that this treatment regimen effectively
decreases body temperature without the occurrence of
hemodynamic side effects. In their control group, anti-
pyretic therapy (0.2 mg/kg diclofenac, 1 g acetamino-
phen) was administered over a 30-minute period. This
infusion rate was associated with a significant CPP
decrease (P = 0.03) and is comparable to our results.
These findings suggest an association of hemodynamic
side effects with the application time of antipyretic ther-
apy. Further studies are needed to investigate whether
continuous low-dose diclofenac should preferably be
used in aSAH patients.
We found an effective reduction of body temperature
after parenteral diclofenac, whereas the degree of tem-
perature reduction and the duration to maximum efficacy
Figure 2 Changes from mean baseline values after parenteral diclofenac (zero on X-axis is the first 10-minute-average interval during
interventions; n = 123). CPP (▼, baseline = 85 ± 1.4 mm Hg; P < 0.001), ICP (■, baseline, 8.6 ± 0.4 mm Hg); and PbtO2 (●, baseline = 28.1 ± 2.2
mm Hg; P < 0.001). The dotted bar illustrates the median diclofenac infusion time (34 minutes; IQR, 20 to 45). Values are presented in mean ±
SEM. CPP, cerebral perfusion pressure; ICP, intracranial pressure; IQR, interquartile range; PbtO2, brain-tissue oxygen tension. Initial CPP decrease
after parenteral diclofenac occurred within the first 10 minutes, indicated as point zero at the X-axis.
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were in line with the literature [10,12] and pharmacologic
properties of diclofenac (half-life, 1 to 2 hours) [32].
This study has several limitations. First, a causal relation
between parenteral diclofenac and PbtO2 decrease cannot be
certainly proven based on our data. Importantly, all continu-
ous physiologic and pharmacologic data as well as interven-
tion time points were exactly recorded with an electronic
chart and patient-management system. Second, this obser-
vational study has no power to compare the effects of differ-
ent antipyretic drugs on PbtO2, which can be demonstrated
only by randomized controlled trials. Third, the infusion
rate was not standardized, which might bias the study
results. Fourth, we did not analyze cerebral autoregulation
or CBF, and microdialysis data must be interpreted cau-
tiously because of limited sample size with simultaneous
PbtO2 recordings available during interventions.
Nonetheless, this is the first study investigating brain-
tissue oxygen tension and cerebral metabolism after par-
enteral diclofenac in poor-grade aSAH patients.
Figure 3 Time-locked changes in PbtO2 from baseline of four different CPP groups (quartiles) representing maximum CPP decrease
observed during the study period.
Figure 4 Correlation between PbtO2 (x) reaching minimum
values after parenteral diclofenac and PbtO2 values before
intervention. Lines represent PbtO2 threshold of 20 mm Hg. The
right lower quadrant indicates PbtO2 values ≥20 mm Hg at baseline
reaching hypoxic values after intervention.
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Conclusions
This study indicates that parenteral diclofenac effectively
reduces body temperature, but may lead to CPP decline
and brain-tissue hypoxia, which are both associated with
poor outcome after SAH. Tight monitoring and awareness
about possible hemodynamic side effects seem mandatory
when using parenteral diclofenac in patients with poor-
grade aSAH.
Key messages
• Tight monitoring of hemodynamic side effects is
mandatory when using parenteral diclofenac in
patients with poor-grade aSAH.
• Parenteral diclofenac after poor-grade aSAH effec-
tively reduces body temperature, but may decrease
MAP, CPP, and brain-tissue oxygen tension.
• PbtO2 <30 mm Hg before parenteral diclofenac
was highly predictive of brain-tissue hypoxia (PbtO2
<20 mm Hg) after intervention.
Additional material
Additional file 1: Flow chart of patients and interventions included
in the study. This file contains a flow chart of patients and interventions
included in or excluded from the study.
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